Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation plus immunotherapy: a one-two punch against metastatic cancer?

NCT ID NCT02843165

Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding stereotactic body radiation therapy (SBRT) to standard checkpoint immunotherapy improves tumor response in 106 people with advanced metastatic cancer. Participants received either immunotherapy alone or immunotherapy plus SBRT to one tumor site. The goal was to see if the combination leads to more tumor shrinkage and longer time without cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Checkpoint blockade immunotherapy (anti-CTLA-4 and anti-PD-1/PD-L1 antibodies) plus stereotactic body radiation therapy (SBRT)
What this could lead to
If it works, this combination could improve tumor shrinkage and delay cancer progression in people with advanced metastatic cancer.
What could go wrong
This is a phase 2 trial with only 106 participants, so results may not apply to everyone. Adding radiation to immunotherapy can increase side effects like inflammation or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

106 people

The number who actually took part.

Started

Sep 2016

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient has one lesion that is treatable with SBRT. * Patient has at least 1 site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) or Magnetic resonance imaging (MRI) which will not be irradiated. * Histological confirmation of malignancy (primary or metastatic tumor). * Patient may have any prior therapy allowed aside from having had prior radiotherapy to the treatment site. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * Patient's screening laboratory values must meet protocol limits. * Patient must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patient has had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * Patient receiving any investigational or experimental agents other than immunotherapy. * Patient who has had any prior radiotherapy to the treatment site(s). * Patient is a pregnant woman (pregnant women are excluded from this study because radiation treatment has known potential for teratogenic or abortifacient effects). * Patient refuses to sign informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic cancer

Contacts and locations

Locations

  • UCSD Moores Cancer Center

    La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.